Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1

Simple item page
dc.contributor.authorGumus, M.
dc.contributor.authorKilickap, S.
dc.contributor.authorSezer, A.
dc.contributor.authorBondarenko, I.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorGogishvili, M.
dc.contributor.authorHe, X.
dc.contributor.authorGullo, G.
dc.contributor.authorRietschel, P.
dc.contributor.authorQuek, R. G.
dc.date.accessioned2024-04-24T08:30:32Z
dc.date.available2024-04-24T08:30:32Z
dc.date.issued2023
dc.identifier.endpageS321en_US
dc.identifier.issue11en_US
dc.identifier.startpageS321en_US
dc.identifier.urihttp://hdl.handle.net/11727/12038
dc.identifier.volume18en_US
dc.identifier.wos001098831600537en_US
dc.language.isoengen_US
dc.relation.journalJOURNAL OF THORACIC ONCOLOGYen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCemiplimaben_US
dc.subjectAdvanceden_US
dc.subjectNSCLCen_US
dc.subjectPatient-reported outcomesen_US
dc.titleDisease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1en_US
dc.typeConference Objecten_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Tıp Fakültesi / Faculty of Medicine